Dianthus Therapeutics DNTH Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Dianthus Therapeutics (DNTH) reported comprehensive income (loss), net of tax, attributable to parent of -$41.9M in Q1 2026.
- How has Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 42.8% year-over-year, from -$29.35M to -$41.9M.
- What is the long-term trend for Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 6.1% compound annual growth rate (CAGR), from -$71.14M to -$84.91M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric measures the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a comprehensive view of the company's financial health by including items that bypass the traditional income statement. This figure is essential for understanding the total economic impact of all financial activities on shareholder value.